Related Experiment Video

Updated: May 18, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer

Mikito Inokuchi1, Tadao Murayama, Mikiko Hayashi

  • 1Departments of Surgical Oncology.

Experimental and Therapeutic Medicine
|September 15, 2012
PubMed

Insights

Increased expression of phosphorylated STAT3 (p-STAT3), mammalian target of rapamycin (mTOR), and epidermal growth factor receptor (EGFR) correlates with poorer outcomes in gastric cancer patients. These signaling proteins are linked to tumor progression and reduced disease-specific survival.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • Signal transducer and activator of transcription 3 (STAT3), mammalian target of rapamycin (mTOR), and epidermal growth factor receptor (EGFR) are key intracellular signaling proteins involved in cell growth and proliferation.
  • These proteins are recognized as potential therapeutic targets for various cancers, including gastric cancer.

Purpose of the Study:

  • To investigate the correlation between the expression of STAT3, mTOR, and EGFR and clinicopathological features in gastric cancer.
  • To assess the relationship between the expression of these proteins and patient outcomes, including survival.

Main Methods:

  • Tumor samples from 126 gastric adenocarcinoma patients were analyzed.
  • Immunohistochemical staining was used to assess the expression of phosphorylated STAT3 (p-STAT3), p-mTOR, and EGFR.
  • Statistical analyses were performed to correlate protein expression with clinicopathological factors and patient survival.

Main Results:

  • Elevated expression of p-STAT3, p-mTOR, and EGFR correlated significantly with advanced tumor invasion, lymph node metastasis, and higher tumor stage.
  • Increased p-STAT3 and EGFR expression were associated with distant metastasis, recurrence, and poorer disease-specific survival (DSS).
  • Higher expression levels of p-STAT3, p-mTOR, and EGFR were progressively linked to worse DSS.

Conclusions:

  • The expression of p-STAT3, p-mTOR, and EGFR is significantly associated with tumor progression and adverse outcomes in gastric cancer.
  • These signaling molecules may serve as important prognostic markers for gastric cancer patients.
  • Interactions among p-STAT3, p-mTOR, and EGFR likely play a crucial role in gastric cancer progression and patient prognosis.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...